Thalidomide and lenalidomide in the treatment of multiple myeloma

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease. Thalidomide, initially introduced for treatment of MM because of its anti-angiogenic properties, has shown remarkable activity alone and in combination with other drugs in patients across all stages of the disease. Given the potential for teratogenicity with thalidomide and the non-haematologic toxicities of the drug, several analogues referred to as "immunomodulatory drugs" (IMiDs) were developed with the intent of enhancing the immunomodulatory effect while minimizing the teratogenic risk. Lenalidomide (CC-5013) and Actimid (CC-4047) are the first such analogues to undergo clinical testing. Lenalidomide has shown impressive activity in relapsed refractory myeloma as well as newly diagnosed disease. The precise mechanism of anti-MM activity of thalidomide and the IMiDs is not clear, but studies suggest that several other mechanisms besides anti-angiogenic effects may play a role. In this paper we review the development, pharmacology, mechanism of action, pre-clinical and clinical efficacy, and the current status of thalidomide and the IMiDs in the treatment of MM.

Original languageEnglish (US)
Pages (from-to)1612-1622
Number of pages11
JournalEuropean Journal of Cancer
Volume42
Issue number11
DOIs
StatePublished - Jul 2006

Fingerprint

Thalidomide
Multiple Myeloma
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
lenalidomide
Pharmacology

Keywords

  • Lenalidomide
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Thalidomide and lenalidomide in the treatment of multiple myeloma. / Kumar, Shaji K; Rajkumar, S Vincent.

In: European Journal of Cancer, Vol. 42, No. 11, 07.2006, p. 1612-1622.

Research output: Contribution to journalArticle

@article{32c5d5d6b0a946f897af4ec715334779,
title = "Thalidomide and lenalidomide in the treatment of multiple myeloma",
abstract = "Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease. Thalidomide, initially introduced for treatment of MM because of its anti-angiogenic properties, has shown remarkable activity alone and in combination with other drugs in patients across all stages of the disease. Given the potential for teratogenicity with thalidomide and the non-haematologic toxicities of the drug, several analogues referred to as {"}immunomodulatory drugs{"} (IMiDs) were developed with the intent of enhancing the immunomodulatory effect while minimizing the teratogenic risk. Lenalidomide (CC-5013) and Actimid (CC-4047) are the first such analogues to undergo clinical testing. Lenalidomide has shown impressive activity in relapsed refractory myeloma as well as newly diagnosed disease. The precise mechanism of anti-MM activity of thalidomide and the IMiDs is not clear, but studies suggest that several other mechanisms besides anti-angiogenic effects may play a role. In this paper we review the development, pharmacology, mechanism of action, pre-clinical and clinical efficacy, and the current status of thalidomide and the IMiDs in the treatment of MM.",
keywords = "Lenalidomide, Multiple myeloma, Thalidomide",
author = "Kumar, {Shaji K} and Rajkumar, {S Vincent}",
year = "2006",
month = "7",
doi = "10.1016/j.ejca.2006.04.004",
language = "English (US)",
volume = "42",
pages = "1612--1622",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Thalidomide and lenalidomide in the treatment of multiple myeloma

AU - Kumar, Shaji K

AU - Rajkumar, S Vincent

PY - 2006/7

Y1 - 2006/7

N2 - Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease. Thalidomide, initially introduced for treatment of MM because of its anti-angiogenic properties, has shown remarkable activity alone and in combination with other drugs in patients across all stages of the disease. Given the potential for teratogenicity with thalidomide and the non-haematologic toxicities of the drug, several analogues referred to as "immunomodulatory drugs" (IMiDs) were developed with the intent of enhancing the immunomodulatory effect while minimizing the teratogenic risk. Lenalidomide (CC-5013) and Actimid (CC-4047) are the first such analogues to undergo clinical testing. Lenalidomide has shown impressive activity in relapsed refractory myeloma as well as newly diagnosed disease. The precise mechanism of anti-MM activity of thalidomide and the IMiDs is not clear, but studies suggest that several other mechanisms besides anti-angiogenic effects may play a role. In this paper we review the development, pharmacology, mechanism of action, pre-clinical and clinical efficacy, and the current status of thalidomide and the IMiDs in the treatment of MM.

AB - Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease. Thalidomide, initially introduced for treatment of MM because of its anti-angiogenic properties, has shown remarkable activity alone and in combination with other drugs in patients across all stages of the disease. Given the potential for teratogenicity with thalidomide and the non-haematologic toxicities of the drug, several analogues referred to as "immunomodulatory drugs" (IMiDs) were developed with the intent of enhancing the immunomodulatory effect while minimizing the teratogenic risk. Lenalidomide (CC-5013) and Actimid (CC-4047) are the first such analogues to undergo clinical testing. Lenalidomide has shown impressive activity in relapsed refractory myeloma as well as newly diagnosed disease. The precise mechanism of anti-MM activity of thalidomide and the IMiDs is not clear, but studies suggest that several other mechanisms besides anti-angiogenic effects may play a role. In this paper we review the development, pharmacology, mechanism of action, pre-clinical and clinical efficacy, and the current status of thalidomide and the IMiDs in the treatment of MM.

KW - Lenalidomide

KW - Multiple myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33746336252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746336252&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.04.004

DO - 10.1016/j.ejca.2006.04.004

M3 - Article

C2 - 16750621

AN - SCOPUS:33746336252

VL - 42

SP - 1612

EP - 1622

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -